Fresenius Invests in BioIntellisense AI Platform
“We made this strategic investment in BioIntelliSense to enable our medical staff to more efficiently and effectively continuously monitor patients, facilitating precise and timely interventions and reducing cost to the system,” explains FMCNA CEO, Bill Valle.
Read the full article » | Posted 09-12-2019
Related Articles
- World Conference in Nephrology Videos on Home Dialysis Posted 04-14-2026
- Vantive’s PD Catheter: Timing, Tips, and Techniques Webinar Posted 04-14-2026
- DaVita Has a New PD Loss-predictive AI Model to Identify Patients at Risk Posted 04-14-2026
- ISPD’s Spotlight Webinar Series 2026 Posted 03-12-2026